Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
KIORA PHARMACEUTICALS INC entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at Underwriting Agreement for public offering of common stock, preferred stock, and warrants, net proce (effective 2023-06-02).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Ladenburg Thalmann & Co. Inc.
- Value
- Underwriting Agreement for public offering of common stock, preferred stock, and warrants, net proce
- Effective
- 2023-06-02
Exact text from the filing
On June 2, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Public Offering”), (i) 1,447,628 shares of common stock (the “Common Shares”), (ii) 3,908 shares of Series F Convertible Preferred Stock (the “Preferred Shares”) convertible into up to 3,552,372 shares of common stock, (iii) Class C Warrants (the “Class C Warrants”) to purchase up to 5,000,000 shares of common stock, and (iv) Class D Warrants (the “Class D Warrants” and, together with the Class C Warrants, the “Warrants”) to purchase up to 5,000,000 shares of common stock, priced at a public offering price of $1.10 per Common Share, Class C Warrant and Class D Warrant or $999.90 per Preferred Share, 909 Class C Warrants and 909 Class D Warrants.
View on SEC.gov